Biology subjects

Rezk, A.

Publications and source records attributed to Rezk, A..

4 recordsLinked to original sources

bioRxiv2026

Limits of marker information transfer]{Limits of marker information transfer in cross-panel cytometry imputation

Marker imputation can bridge cytometry datasets acquired with different panels and platforms. Its validity depends on whether common markers retain information about unmeasured target markers and whether those relationships transfer across assay contexts. We evaluated these limits in two paired flow cytometry-CyTOF cohorts comprising 134 patients and 257 specimens. A patient-held-out framework distinguished within-platform same-cell reconstruction from cross-platform distribution translation without cell correspondence. We compared conventional machine-learning and deep generative estimators with median imputation and used permutation controls to estimate the contributions of patient matching and source-exclusive markers. Evaluation covered marker values, specimen distributions, phenotype utility, and directional predictive relationships among markers. Within platforms, exact k-nearest neighbors reduced mean absolute error by 12.8-35.0% relative to median imputation. However, the median-based reconstructions were contracted, with a median ratio of predicted to observed interquartile range below 1 in every context and evaluable population. Patient matching improved cross-platform distribution recovery, whereas adding source-exclusive markers or higher-capacity estimators did not consistently produce net gains. In the independently annotated acute myeloid leukemia (AML) cohort, reconstructed markers largely preserved broad-lineage classification but did not recover fine-phenotype information available through direct measurement. In AML-CyTOF, the measured full panel outperformed the reconstructed representation by 10.25 percentage points for fine phenotypes. Predictive relationships among markers were context-specific. Most targets were better explained by several markers than by one. Marker selection based on these relationships showed a trade-off between panel size and pairwise coverage. Paired samples and imputation can therefore connect selected marker distributions across panels but should not be treated as substitutes for direct measurement. Cross-panel cytometry should be evaluated with patient-held-out tests matched to the resolution of available ground truth and the intended downstream use.

bioinformatics↗

bioRxiv2025

Abnormal pro-inflammatory immune cell responses precede clinical onset of hypertensive disorders of pregnancy

BackgroundHypertensive disorders of pregnancy (HDP) are significant contributors to maternal morbidity and mortality as well as to long-term cardiovascular health, with an inequitable burden among Black individuals. While there is growing interest in the possibility that inflammatory responses are involved with HDP, work to date has primarily been cross-sectional, and immune cell profiling has focused on cell phenotyping that may not capture relevant functional properties of the immune cells. ObjectiveTo examine whether an inflammatory cellular response is found in the blood of pregnant women preceding the clinical onset of HDP. Study designThis nested case-control study included 27 pregnant women who later developed HDP and 73 who had a healthy pregnancy delivered at term, all of whom provided blood samples during the second trimester. ResultsWe observed a greater abundance of peripheral blood T cells in individuals later diagnosed with HDP. Among these were CD161+ CD4 T cells that showed increased expression of pro-inflammatory cytokines, including GM-CSF and TNF. Similarly, monocytes from these individuals exhibited increased expression of pro-inflammatory cytokines. Anti-inflammatory T cells and monocytes were not altered in those with versus without a future diagnosis of HDP. ConclusionWe identify a pro-inflammatory cellular immune signature in pregnant individuals destined to have HDP. Immune signatures may serve as a new biomarker to identify subsets of individuals at particular risk for HDP and/or point to new therapeutic targets to prevent HDP.

immunology↗

bioRxiv2025

Pediatric cerebrospinal fluid immune profiling distinguishes pediatric-onset multiple sclerosis from other pediatric-onset acute neurological disorders

The cerebrospinal fluid (CSF) provides a unique glimpse into the central nervous system (CNS) compartment and offers insights into immune processes associated with both healthy immune surveillance as well as inflammatory disorders of the CNS. The latter include demyelinating disorders, such as multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), that warrant different therapeutic approaches yet are not always straightforward to distinguish on clinical and imaging grounds alone. Here, we establish a comprehensive phenotypic landscape of the pediatric CSF immune compartment across a range of non-inflammatory and inflammatory neurological disorders, with a focus on better elucidating CNS-associated immune mechanisms potentially involved in, and discriminating between, pediatric-onset MS (MS) and other pediatric-onset suspected neuroimmune disorders, including MOGAD. We find that CSF from pediatric patients with non-inflammatory neurological disorders is primarily composed of non-activated CD4+ T cells, with few if any B cells present. CSF from pediatric patients with acquired inflammatory demyelinating disorders is characterized by increased numbers of B cells compared to CSF of both patients with other inflammatory or non-inflammatory conditions. Certain features, including particular increased frequencies of antibody-secreting cells (ASCs) and decreased frequencies of CD14+ myeloid cells, distinguish MS from MOGAD and other acquired inflammatory demyelinating disorders.

immunology↗

bioRxiv2022

Human glioblastoma cell motility depends on the activity of the cysteine metabolism enzyme 3-Mercaptopyruvate sulfurtransferase

Cancer cells in similar functional states are found in all glioblastoma, despite the genomic heterogeneity observed between and within these brain tumors. Metabolism being downstream of all signaling pathways regulating cell behaviors, we looked for metabolic weaknesses in link with motility, a key functional state for glioblastoma aggressiveness. A signature-driven data reduction approach highlighted motile cells present in thirty tumors from four independent single-cell transcriptomic datasets. Analyses integrating trajectory modeling disclosed, as characteristic of motile cells, enhanced oxidative stress coupled with mobilization of the cysteine metabolism enzyme 3-Mercaptopyruvate sulfurtransferase (MPST). The soundness of this prediction was verified using migration and invasion assays with patient-derived cells and tissue organoids. Pharmacological and genetic manipulations showed that enhanced ROS production and MPST activity are required for the cells motility. Biochemical assays indicated that MPST acts by protecting protein cysteine residues from dismal hyperoxidation. In vivo, MPST knockdown translated in reduced tumor burden, and a robust increase in mice survival. These results show that enhanced oxidative stress coupled with MPST mobilization plays a key role in glioblastoma cell motility.

cancer biology↗